Viking Therapeutics, Inc. (VKTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments155,485202,103248,386275,638301,52020,576
Cash and cash equivalents36,63226,37129,1178,37724,7798,988
Short-term investments118,853175,732219,269267,261276,74111,587
Other undisclosed current assets11,5558,4257,7187,8636131,276
Total current assets:167,040210,528256,104283,501302,13321,852
Noncurrent Assets
Operating lease, right-of-use asset1,41825321598
Deposits noncurrent assets3333292929 
Other undisclosed noncurrent assets387648128150270
Total noncurrent assets:1,489134398755179270
TOTAL ASSETS:168,529210,662256,502284,256302,31222,121
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21,6438,74911,7996,4754,5503,808
Interest and dividends payable    22
Accounts payable8,5291,4443,9882,4319591,530
Accrued liabilities13,1147,3057,8114,0443,5912,257
Debt    302 3,451
Other undisclosed current liabilities30429330  1,398
Total current liabilities:21,9478,77812,1296,7774,5508,657
Noncurrent Liabilities
Long-term debt and lease obligation:   29360  
Liabilities, other than long-term debt1,260   12 
Deferred rent credit     12
Operating lease, liability1,260 29360
Other undisclosed noncurrent liabilities   (29)   
Total noncurrent liabilities:1,260 2936012 
Total liabilities:23,2078,77812,1587,1374,5628,657
Equity
Equity, attributable to parent145,322201,884244,344277,119297,75013,465
Common stock111110
Treasury stock, value(6,795)     
Additional paid in capital445,267425,614412,589405,803401,09094,339
Accumulated other comprehensive income (loss)(1,102)(549)(54)12(423)(20)
Accumulated deficit(292,049)(223,182)(168,192)(128,697)(102,918)(80,855)
Total equity:145,322201,884244,344277,119297,75013,465
TOTAL LIABILITIES AND EQUITY:168,529210,662256,502284,256302,31222,121

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues   404  
Gain (loss) on disposition of assets for financial service operations (42) 404(12)
Gross profit:   404  
Operating expenses(70,355)(55,682)(42,662)(32,687)(26,161)(19,070)
Other undisclosed operating income (loss) 42 (40)(4)12 
Operating loss:(70,355)(55,682)(42,662)(32,687)(26,161)(19,070)
Nonoperating income (expense)271(3,207)(641)6,4314,025(1,507)
Investment income, nonoperating(1,217)(3,906)(3,808)(477)(73) 
Other nonoperating income (expense)1,4886923,1676,9084,098(1,507)
Loss from continuing operations before income taxes:(70,084)(58,889)(43,303)(26,256)(22,136)(20,578)
Income tax expense (benefit) (1)(2)12,7247,8338,984 
Other undisclosed loss from continuing operations      
Loss from continuing operations:(70,085)(58,891)(30,579)(18,423)(13,152)(20,578)
Loss before gain (loss) on sale of properties:(58,891)(30,579)(18,423)(13,152)(20,578)
Other undisclosed net income (loss)1,2183,901(8,916)(7,356)(8,911) 
Net loss available to common stockholders, diluted:(68,867)(54,990)(39,495)(25,779)(22,063)(20,578)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(68,867)(54,990)(39,495)(25,779)(22,063)(20,578)
Comprehensive loss:(68,867)(54,990)(39,495)(25,779)(22,063)(20,578)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(553)(495)(66)435(403)(13)
Comprehensive loss, net of tax, attributable to parent:(69,420)(55,485)(39,561)(25,344)(22,466)(20,591)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: